Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study

Shir Azrielant, Shmuel Tiosano, Abdulla Watad, Naim Mahroum, Aaron Whitby, Doron Comaneshter, Arnon D. Cohen, Howard Amital

    Research output: Contribution to journalArticlepeer-review

    29 Scopus citations

    Abstract

    Autoimmune conditions reflect dysregulation of the immune system; this may be of clinical significance in the development of several malignancies. Previous studies show an association between systemic lupus erythematosus (SLE) and the development of malignancies; however, their investigations into the development of specific malignancies are inconsistent, and their external validity may be questionable. The main objective of this study is to investigate the association between the presence of SLE and various malignancies, in a large-scale population-based study. Data for this study was collected from Clalit Health Services, the largest state-mandated health service organization in Israel. All adult members diagnosed with SLE were included (n = 5018) and their age and sex-matched controls (n = 25,090), creating a cross-sectional population-based study. Medical records of all subjects were analyzed for documentation of malignancies. Logistic regression models were built separately for each malignant condition, controlling for age, gender, BMI, smoking, and socioeconomic status. Diagnosis of malignancy (of any type) was more prevalent in the SLE population (odds ratio [OR] 3.35, 95% confidence interval [CI] 3.02–3.72). SLE diagnosis was also found to be independently associated with higher proportions of non-Hodgkin lymphoma (OR 3.02, 95% CI 2.72–3.33), Hodgkin lymphoma (OR 2.43, 95% CI 1.88–2.99), multiple myeloma (OR 2.57, 95% CI 1.85–3.28), cervix uteri malignancies (OR 1.65, 95% CI 1.10–2.20), and genital organ malignancies (OR 2.32, 95% CI 1.42–3.22), after adjustment for confounding variables. The presence of an SLE diagnosis was found to be independently associated with higher proportions of malignancies, particularly hematologic malignancies. These findings should be considered while treating SLE patients, and possibly supplement their screening routine.[Figure not available: see fulltext.].

    Original languageEnglish
    Pages (from-to)464-469
    Number of pages6
    JournalImmunologic Research
    Volume65
    Issue number2
    DOIs
    StatePublished - 1 Apr 2017

    Keywords

    • Cancer
    • Hodgkin’s disease
    • Lung cancer
    • Lymphoma
    • Smoking
    • Systemic lupus erythematosus

    ASJC Scopus subject areas

    • Immunology

    Fingerprint

    Dive into the research topics of 'Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study'. Together they form a unique fingerprint.

    Cite this